• Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports

  2022-02-20

• Evaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics

  2022-02-05

• Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors

  2022-01-01

• The COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease

  2022-01-01

• A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development

  2010-01-01